ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,473.23
0.77%
Dow Jones
38,778.10
0.49%
US Dollar vs MXN
18.5392
0.02%
Brent Oil
83.625
-0.33%
Bitcoin
65,702.80
-1.18%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Gossamer Bio Inc (GOSS)

  7. Gossamer Bio Inc (GOSS) Noticias

GOSS

Gossamer Bio (GOSS)

Gossamer Bio Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GOSS
FechaHoraFuenteTítuloSímboloCompañía
10/06/202415:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
07/06/202415:30Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GOSSGossamer Bio Inc
06/06/202420:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
14/05/202415:01Business WireGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceNASDAQ:GOSSGossamer Bio Inc
07/05/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GOSSGossamer Bio Inc
07/05/202415:01Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
06/05/202406:30Business WireGossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other IndicationsNASDAQ:GOSSGossamer Bio Inc
03/05/202407:02Business WireGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineNASDAQ:GOSSGossamer Bio Inc
12/03/202406:31Business WireGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
05/03/202406:37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GOSSGossamer Bio Inc
05/03/202406:32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:GOSSGossamer Bio Inc
05/03/202406:31Business WireGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
13/12/202315:01Business WireGossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023NASDAQ:GOSSGossamer Bio Inc
05/12/202316:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
05/12/202306:01Business WireGossamer Bio Appoints Bob Smith as Chief Commercial OfficerNASDAQ:GOSSGossamer Bio Inc
29/11/202306:01Business WireGossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
09/11/202306:31Business WireGossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
03/10/202315:08Business WireGossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical AffairsNASDAQ:GOSSGossamer Bio Inc
07/09/202306:44Business WireGossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023NASDAQ:GOSSGossamer Bio Inc
28/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GOSSGossamer Bio Inc
28/08/202315:29Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GOSSGossamer Bio Inc
21/08/202315:01Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:GOSSGossamer Bio Inc
18/08/202307:41Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GOSSGossamer Bio Inc
18/08/202307:38Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:GOSSGossamer Bio Inc
17/08/202315:01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:GOSSGossamer Bio Inc
08/08/202315:01Business WireGossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
07/08/202315:44Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:GOSSGossamer Bio Inc
28/07/202314:46Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:GOSSGossamer Bio Inc
24/07/202315:16Business WireGossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE ResultsNASDAQ:GOSSGossamer Bio Inc
20/07/202306:56Business WireGossamer Bio Announces $212 Million Private Placement FinancingNASDAQ:GOSSGossamer Bio Inc
 Showing the most relevant articles for your search:NASDAQ:GOSS

Su Consulta Reciente

CCOM
US500
US 500
USOTC
BNPQY
BNP Paribas (QX)
COIN
ETHUSD
Ethereum
AMEX
XLF
Financial Select Sector
USOTC
ADDYY
Adidas (QX)
FX
EURUSD
Euro vs US Dollar
NYSE
MRK
Merck
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
USOTC
RHHBY
Roche (QX)
CCOM
OILBRENT
Brent Oil
NYSE
XOM
Exxon Mobil
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados